(NASDAQ: NEO) Neogenomics's forecast annual revenue growth rate of 8.88% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.61%.
Neogenomics's revenue in 2026 is $745,969,000.On average, 15 Wall Street analysts forecast NEO's revenue for 2026 to be $104,773,606,659, with the lowest NEO revenue forecast at $101,333,411,432, and the highest NEO revenue forecast at $109,118,773,758. On average, 14 Wall Street analysts forecast NEO's revenue for 2027 to be $114,971,793,269, with the lowest NEO revenue forecast at $109,870,095,728, and the highest NEO revenue forecast at $120,999,296,565.
In 2028, NEO is forecast to generate $125,446,028,852 in revenue, with the lowest revenue forecast at $118,866,427,609 and the highest revenue forecast at $131,904,533,140.